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Abstract
The intra-articular injection of high molecular weight hyaluronic acid (HA) has been reported to be an effective treatment for
pain of osteoarthritis of the knee. However, the mechanism by which HA exerts its effect is unknown. To explore HA’s influence on
the growth of U937 human macrophages, cells were incubated for 168 h with three concentrations, I , 0.1 and 0.01 mg/mL, of
Hyalgan“, a high molecular weight HA preparation. At 24-h increments, the cells were examined for proliferation, cell cycle distribution as well as the number of apoptotic and dead cells. Exposing macrophages to 1 mg/mL HyalganO significantly reduced the
rate of cellular proliferation and altered the cell cycle distribution to yield decreased proportions of GOfG1 cells but increased S and
G2/M cells. Concomitantly, a 10-fold increase in apoptotic cells and a 12-fold increase in dead cells were observed. The population
doubling time (PDT) for cells treated with 1 .O mg/mL Hyalgan‘”’increased from 23.6 to 52.9 h. By contrast, the two lower HyaIganO
concentrations significantly promoted macrophage proliferation in a dose-dependent manner. They also increased the proportion of
G2/M cells, but had no effect on the number of apoptotic or dead cells. The PDTs of 21.5 and 22.2 h were less than the control time
of 23.6 h. These results demonstrate that Hyalgan@concentrations have a differential effect on macrophage growth dynamics and
suggest an anti-inflammatory effect at high HA concentrations.
0 2003 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.
Kqwortis: Hyalgan“: Hyaluronic acid: Macrophage; Proliferation: Apoptosis; Osteoarthritis

Introduction

The intra-articular injection of hyaluronic acid (HA)
has been approved by the United States Food and Drug
Administration as a treatment for the pain of osteoarthritis (OA) of the knee which is refractory to conservative non-pharmacologic therapy and to simple
analgesics [ 3 11. This joint fluid therapy, sometimes
termed viscosupplementation, typically requires multiple weekly injections of high molecular weight HA.
Injectable HA is available in the United States as Hyalgan‘ (Sanofi, New York, NY), Synvisca (Genzyme/
Biomatrix”, Ridgefield, NY), or Supartz@ (Smith &
Nephew, Memphis, TN), all of which are purified from
rooster comb HA. The efficacy of joint fluid therapy was
first reported in 1974 [30] when a statistically significant
reduction in pain and improved activity in patients with
OA were noted. Subsequent studies of OA patients have
*Corresponding author. Tel.: +I-616-957-6083; fax: +I-616-957650 I .
E-n7ai/ utfiirrss: dehe@calvin.edu (D.H. DeHeer).

reported transient analgesia and improved activity following joint fluid therapy [ 1,24,29,43]. More recently,
HA injections have been reported to be an effective
conservative treatment for rotator cuff tears [35] and an
adjunct to arthrocentesis for temporomandibular joint
internal derangements [3].Widespread use of HA in OA
patients, however, merits additional investigation due to
the reported high placebo effect associated with joint
fluid therapy as well as a lack of uniform, cost-effective
benefits [4,10,42].
The mechanism of HA’s action is poorly understood.
Joint fluid therapy originally was based on the observations that the viscosity and elasticity of synovial fluid
are reduced in human arthritis [7] and that these fluid
features result from the unique rheological properties of
HA [6]. Also, HA concentration and molecular size are
reduced in human and equine arthritis [7]. The clinical
benefits of exogenous HA therefore were thought to
result from restoration of synovial fluid’s viscosity and
elasticity. With the observation that HASmean intrasynovial half-life is comparatively short, less than 24 h in
animal studies [22], restoration of rheological properties
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alone could not account for joint fluid therapy's longterm benefit.
More recently, HA was shown to directly affect cellular proliferation or apoptosis. At low concentrations,
HA of high molecular weight, similar to that of Hyalgan@,generally was reported to stimulate cellular proliferation [ 18,191 while high concentrations, such as
those in synovial fluid, inhibited proliferation [12,15,27].
In separate studies, Hyalgan@ reduced anti-Fas-mediated apoptosis [23] while HA directly reduced apoptosis
[37]. Both proliferative and apoptotic effects are likely
mediated by the binding of HA to CD44, the major receptor for HA on cell surfaces [5], since receptor crosslinking with specific antibody enhances both cellular
activities [5,14,37].
In diseases like OA that are associated with cellular,
cartilaginous, crystal, and particulate debris, synovial
macrophages are important for removing debris and for
mediating inflammation. Synovial macrophages exist in
an environment that normally contains a high concentration of high molecular weight HA [7], but both
concentration and size may be reduced in acute inflammation or chronic disease due to hyaluronidases
and oxygen radicals [21,28]. HA's influence on several
cell types has been reported, but its influence on macrophages has not been studied previously. Further, HA's
influence on cellular growth, a dynamic that additively
combines the net effects of cellular proliferation and
cellular apoptosis, has not been reported previously.
The purpose of the present study was to determine
the net effect of varying concentrations of high molecular weight HA on macrophage population growth by
measuring the individual influences of proliferation and
apoptosis. To avoid potential cellular activation due to
phagocytosis of oncotic cells and/or cellular debris,
U937 macrophages, which are not phagocytic [32], were
used. The results demonstrate that HA at a high concentration negatively influences cell proliferation while
inducing apoptosis. Lower HA concentrations failed to
induce these effects. These findings show that HA has a
dose-dependent regulatory influence on macrophages,
and suggest an anti-inflammatory effect at high HA concentrations.

Materials and methods
CPll culrurc

The U937 human macrophages cell line (American Type Culture
Collection, Manassas, VA) was utilized in all experiments. Cells were
cultured at 37 "C in a humidified atmosphere of 5% COz in RPMI1640, pH 7.2, supplemented with 10'%tfetal bovine serum (FBS, Gibco,
Grand Island. NY), 2 mM L-glutamine and 1 mM sodium pyruvate.
Stock U937 cultures were maintained in the exponential growth phase,
below 5.0 x los cellsiml. For experiments cells were seeded in 24-well
plates (Corning Costar, Cambridge, MA) in 900 pL of medium plus
100 pL of Hyalgan" (Sanofi Synthelabo, New York, NY) or phosphate
buffered saline (PBS). pH 7.2 diluted in medium to the appropriate
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Table I
Plating concentrations of U937 macrophages for cell growth experiments
~~

Hyalgan@exposure time ( h )

Plating concentration (cellslmL)

0
24
48
72
96
120
144
168

1,000,000
640.000
320,000
160,000
80,000
40,000
20,000
10,000

At eight times (Hyalgan" exposure time) cells were seeded in 24-well
plates at varying concentrations (plating concentration) and maintained in culture for the duration of the experimental period. The
concentrations were calculated to yield lo6 cells at the end of the 168-h
period based on a PDT of approximately 24 h.

concentrations. Cell numbers and population doubling time (PDT)
were determined by counting with a hemacytometer. Viability was
assessed by trypan blue dye exclusion.
E.~perimmtaldesign

U937 macrophages were seeded at 24-h intervals during a 168-h
period using replicates for each of four assay types: proliferation. cell
cycle distribution, apoptotic cells, and dead cells. To perform all analyses at one time. increasing concentrations of cells were seeded at each
interval and maintained in culture for the duration of the experiment
(Table I). Seeding densities were chosen to provide a final concentration of 10' ceiislmL by the end of the experimental period assuming a
PDT of approximately 24 h [9]. Experimental wells contained I , 0.1.
and 0.01 mg/mL Hyalgan~'. Control wells contained PBS. the diluent
for Hyalgan").
Floiv cytometric unulyseb

Analysis of proliferation, cell cycle distribution, apoptotic and dead
cells was performed using a FACSort flow cytometer (Becton Dickinson, San Jose, CA) equipped with a 488 nm excitation laser. For each
sample, a minimum of 15,000 whole cell o r nuclei events was captured
using exclusionary gating of the forward vs. side scatter plots. Data
acquisition was performed using the FL-I green fluorescence (530 nm)
or the FL-2 red fluorescence (>600 nm) detection channel with Cell
Quest data acquisition software (Becton Dickinson, San Jose. CA).
Cell proliferation analyses

Immediately before culture U937 macrophages were labeled with
the green Puorescent dye, carboxyfluorescein diacetate succinimidyl
ester (CFDA, SE, Molecular Probes. Eugene, OR) as previously described [25]. Non-fluorescent CFDA, SE spontaneously crosses the cell
membrane, is converted to a green fluorescent succinimidyl ester
(CFSE) by intracellular esterases, and forms stable. long-term bonds
with intracellular proteins. A 5 mM CFDA, SE stock in dimethylsulfoxide was diluted 11100 in PBS, and 110 pL was added with rapid
mixing per 1 mL of cells suspended in PBS. After a 5 min incubation at
room temperature, the cells were washed three times with PBS containing 5% FBS, and resuspended in RPMI-1640 at the required
seeding der.sity. After incubation, the cells were washed twice in PBS
containing 2% FBS and 0.1% sodium azide. They were analyzed for
CFSE fluorescent intensity by flow cytometry.

Cell cycle distribution unuljws
The cell cycle distribution of U937 inacrophages was determined by
quantifying DNA in isolated nuclei using propidium iodide (PI) [20].
PI staining measures the aneuploidy of each cell and can be translated
into three distinct cycling phases: GOlGI, S, and G2/M [20]. U937 cells
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were washed twice with PBS containing 2% FBS and 0.1'%1sodium
azide. To isolate and slain nuclei, cells were resuspended in 1 mL of a
modified Vindelov butTer [41] containing 50 mg/mL PI, 0.7 U/mL
RNase, and 0.I'% Igepal CA-630. After a 10 min incubation at room
temperature, flow cytometry was performed using the FL-2 detection
channel. Further analysis utilized Modfit LT software (Verity Software
House, Topsham, ME).
Quunrifj!ing UpOploliC' and deud

I
t - 0 01 mg/mL

t

o 1 mg/mL
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Viable, apoptotic, and dead cells were measured by flow cytometry
after staining with YO-PRO-]/PI (Molecular Probes, Eugene, OR)
according to the manufacturer's instructions. For gating calibration of
the flow cytometer. apoptotic and dead cells were prepared by exposing U937 macrophages to 20 pM camptothecin (Sigina-Aldrich, St.
Louis, MO) for 4 h. The green fluorescent dye YO-PRO-I selectively
crosses the membranes of apoptotic, but not viable cells. The red fluorescent dye PI does not cross the membranes of live o r apoptotic cells,
but easily enters dead cells and strongly binds to nucleic acids. With
YO-PRO-l/PI staining. apoptotic cells exhibit green fluorescence, dead
cells display both green and red fluorescence, and live cells show little
or no fluorescence.

Anulysey,for CD44 und H A hinriinx

To demonstrate that the macrophages used in the present study
possessed surface CD44 receptors capable of binding HA, cells were
stained with fluorescent anti-CD44 antibody and with fluorescein
(F1TC)-conjugated HA. I 0' macrophages were washed and incubated
with 20 pL fluorescein-conjugated anti-CD44 antibody (Immunotech,
Marseille. France) a t 4 "C for 20 min. A mouse lgGl antibody (Becton
Dickinson, San Jose, CA) was used as an isotype control. After washing the cells were resuspended in 200 pL of PBS containing 1% bovine
serum albumin (BSA) and 1% paraformaldehyde. To detect HA
binding, an additional 10' cells were incubated with 1 mg/mL fluorescein-conjugated HA (mean molecular weight 10' Da, CarboMer,
Inc., Westborough. MA) at 4 "C for 30 min. In inhibition studies, 10'
cells treated with conjugated HA were pre-incubated with 0.5 ug/uL rat
anti-CD44 IgG (Zymed Laboratories, San Francisco, CA) diluted in
PBS containing 1% BSA at 4 "C for 30 min. Negative control cells were
treated only with the unconjugated anti-CD44 antibody. All cell
preparations were examined by flow cytometry for green fluorescence
using the FL-I detection channel.
Siutisticul unu1yse.s

Cell enumeration data were expressed as means with error bars
indicating one standard deviation. Mean values from each time point
using experimental cells cultured with HA were compared to control
cells cultured without H A using a Student's t-test assuming unequal
variances. A probability of p < 0.05 was considered to be statistically
significant.

Results
Hyulguri@ has u di'erential
eration
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To determine Hyalgan@"seffect on cellular proliferation, macrophages were labeled with the green fluorescent dye, CFDA, SE and incubated with three
concentrations of HyalganO for a maximum of 168 h.
Fluorescent intensity was measured by flow cytometry
at 24-h intervals during the experimental period. The
results (Fig. 1) demonstrated that the 1 mg/mL Hyalgan@concentration inhibited macrophage proliferation,
compared to control cultures, as evidenced by increased
fluorescence beginning at 72 h. By comparison, cells

0

24

48

72

96

120

144

168

Time of Hyalgan Exposure (Hours)
Fig. I . Effect of Hyalgdn' concentration on macrophage proliferation.
U937 cells were labeled with CFDA. SE which spontaneously permeates cells and is converted to an ester, CFSE, that is retained within
the cells. As cells divide, the fluorescent dye is divided between the
daughter cells. Therefore, CFSE fluorescent intensity is inversely
proportional to the number of cellular divisions. Cells were cultured
with various concentrations of Hyalgan@ or PBS (control) for eight
24-h periods ranging from 0 to 168 h. At the end of each culture period, a minimum of 15.000 cells from each culture was analyzed by
flow cytometry for CFSE fluorescent intensity. Percent of control was
calculated as (CFSE intensity of Hyalgan"-treated cells)/(CFSE intensity of control cells) x 100.

incubated with the two lower Hyalgan' concentrations,
0.01 and 0.1 mg/mL, exhibited less fluorescence and
therefore increased proliferation. The difference between
these inhibitory and stimulatory effects was substantial.
At 168 h, the fluorescence of cells incubated with 1 mg/
mL HyalganO was 381% of control cells. However,
cells exposed to the two lower Hyalgan@concentrations
displayed only 11% and 15% of control-cell fluorescence.
Together these data demonstrate that HyalganB has a
differential, dose-dependent effect on the rate of macrophage proliferation.
To further explore Hya1gan'"s effects on proliferation, cell numbers were determined by microscopic examination. The number in Hyalgan@-treated cultures
was compared to the corresponding number of control
cells, and both numbers were compared to the initial
seeding density to determine the PDT. The results (Fig.
2(A)) confirmed that 1 mg/mL Hyalgan@ decreased cell
number while the two lower Hyalgan@ concentrations
stimulated proliferation. Notably, as shown by comparing seeded and 1 mg/mL Hyalgan@ numbers, cells
exposed to the high HyalganO concentration still proliferated. However, the rate was substantially slowed
(compare the control and 1 mg/mL cell numbers). The
calculated PDTs supported these observations. Control
macrophages at 168 h had a baseline PDT of 23.6 h.
HyalganO at 1 mg/mL slowed the PDT to 52.9 h while
the 0.1 and 0.01 mg/mL concentrations yielded PDTs
of 21.5 and 22.2 h, respectively. Hyalgan@"sdifferential
effect was readily apparent when cell counts were expressed as a percent of Hyalgan@-negativecontrol (Fig.
2(B)). Over the 168-h experimental period, the 1 mg/mL
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Fig. 2. Effect of Hyalgan'"' concentration on macrophage population
growth. U937 cells were cultured with various concentrations of Hyalgan'",or PBS (control) for seven periods ranging from 24 to 168 h. At
the end of each period, cells were stained with trypan blue and counted
using a heniacytometer. (A) The number of HyaIgan'4reated cells as
compared to the number of Hyaigan'"-negative control cells and the
initial seeding number at each time point. (B) The number of Hyalgan"-treated cells is shown as a percent of the corresponding number
or control cells at each time point. Each point is the mean of 16 replicxtes. Error bars show one standard deviation. The number of Hyalgan"-treated cells at all concentrations and at all time points was
significantly different from the number of control cells ( p < 0.05).
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Hyalgan" concentration progressively reduced the number of macrophages in culture to less than 1% of the
control level. This inhibition was statistically significant
at all time points 0, < 0.01). The two lower Hyalgan@
concentrations stimulated macrophage proliferation by
161% and 123'%1,respectively. These increases were statistically significant at all intervals (p < 0.01). At all
concentrations, Hyalgan@'seffects were apparent within
24 h and progressed in a time-dependent manner.
Hydgun@ chfiJc;rtwriullyinfluences the cell cycle distrihution
H yalgan@"s influence on cellular proliferation suggested that it might also affect the cell cycle distribution
of macrophages. To test this possibility, nuclear DNA
from control and experimental cells was labeled with PI
and analyzed by flow cytometry. The results showed
that, in general, the highest HyalganO concentration affected the cell cycle distribution differently than the
two lower concentrations. In cultures with 1 mg/mL

0

24

48
72
96
120
Time of Hyalgan Exposure (Hours)

Fig. 3. Influence of Hyalgan' concentration on macrophage cell cycle
distribution. Cells were cultured with medium containing various
concentrations of Hyalgan@o r PBS (control) for eight periods ranging
from 0 to 168 h. At the end of each period, the cell cycle distribution o f
at least 15,000 nuclei stained with PI was determined by flow cytometry. (A) Cells in the GOIGI phase. (B) Cells in the S phase. (C) Cells
in the G21M phase. Each point is the percent of total Hyalgan'"-treated
or control cells at that time period.

Hyalgan@, the proportion of cells in the GOlG1 phases
progressively increased through the first 72 h of incubation (Fig. 3(A)). Thereafter, the proportion decreased.
After 72 h the proportions in the S phase (Fig. 3(B)) and
the G2/M phases (Fig. 3(C)) also increased. These data
suggest that Hyalgan@at a high concentration promotes
cell cycle transit from GO/Gl to the S and G2/M phases,
or that cells in the GO/Gl phase are eliminated, thereby
leaving a higher proportion of cells in the S and G2/M
phases.
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The cells exposed to the two lower Hyalgan@ concentrations exhibited GOiG1 and S phase distributions
similar to those of control cells (Fig. 3(A) and (B)). The
exception was the increased proportions in the G2/M
phases throughout the 168-h time course (Fig. 3(C)).
This observation is consistent with a dose-dependent
proliferative effect.
Hyalgun@ has u diferentid @ect on apoptosis and cell
death
Hyalgana”s negative influence on cellular proliferation and GO/Gl phase distribution suggested that it
might induce apoptosis and cell death. To test that
possibility, a flow cytometric method using fluorescent
dyes was employed to directly enumerate apoptotic and
dead cells. Hyalgan@ at 1 mg/mL stimulated an immediate increase in apoptotic cell number, which peaked at
8.5% of the total cell population at 120 h (Fig. 4(A)).
Similarly, Hyalgan@stimulated a progressive increase in
the proportion of dead cells beginning at 72 h, which at
its maximum accounted for 30.9% of all remaining intact cells (Fig. 4(B)). Thus, Hyalgan@ at 1 mg/mL induced a 10-fold increase in apoptotic cells and a 12-fold
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U937 cells have .surji~-ereceptors that bind hyaluronic
acid
To document that U937 macrophages possessed
surface CD44 receptors capable of binding HA, cells
were incubated with a FITC-conjugated anti-CD44 antibody or with FITC-conjugated HA and examined by
flow cytometry. The results (Fig. 6) demonstrated a 128fold increase in fluorescent intensity following exposure
to the anti-CD44 antibody or a 217-fold increase after
incubation with the conjugated HA (Fig. 6). Prior incubation of cells with an anti-CD44 antibody reduced
the FITC-HA binding by 94%. These results demonstrate CD44’s presence on U937 macrophages as well as
its ability to bind HA, thereby suggesting one mechanism whereby Hyalgan@ could influence cellular proliferation and apoptosis.

168

Time of Hyalgan Exposure (Hours)
L

increase in dead cells. By contrast, cells treated with 0.1
or 0.01 mg/mL Hyalgan@ demonstrated no increase in
the proportion of apoptotic or dead cells throughout the
experiment (Fig. 4(A) and (B)). These results show that
HyalganO at a high concentration induces cell death via
apoptosis. Overall, the reduced cell numbers following
Hyalgan@exposure result from both reduced proliferation and induced cell death.
Hyalgan@’sability to induce cell death also was apparent microscopically. Macrophages exposed to 1 mg/
mL Hyalgan@ exhibited reduced size, increased granularity, budding, and fragmentation (Fig. 5), morphological features consistent with apoptosis. The
appearance of cells incubated with the lower concentrations of HyalganO was indistinguishable from that of
control cells (data not shown).

Discussion

15

-z 25.4 201

t0.1 mg/rnL
I

U 1 rnalmL

/

’0

4

I

m

c

n 0-1
0

I

24

48

72

96

120

144

168

Time of Hyalgan Exposure (Hours)

Fig. 4. Influence of HyalganO concentration on the induction of
apoptosis and cell death. Cells were cultured with various concentrations of Hyalgan” or PBS (control) for eight periods ranging from 0 to
168 h. At the end of each period, cells were stained with the fluorochromes YO-PRO-I and PI which can be used to detect apoptotic and
dead cells by flow cytometry. (A) YO-PRO-1-stained apoptotic cells.
(B) PI-stained dead cells. Each point is the percent of total Hya1gan”treated or control cells at that time period.

This study of Hyalgan@”s effects on overall cell
growth has three major conclusions: (1) 1 mg/mL Hyalgan@slows the rate of proliferation, beginning as early
as 24 h, but does not arrest cell division, while low
Hyalgan@ concentrations stimulate proliferation without altering the cell cycle (Figs. 2 and 3); (2) the high
Hyalgan@ concentration induces apoptosis and cell
death, which further reduces cell number, but lower
Hyalgan@ concentrations fail to induce apoptosis (Fig.
4); (3) the progressive increase in cell mortality following exposure to 1 mg/mL Hyalgan@ coincides with an
abrupt change in the cell cycle distribution after 72 h in
which the majority of the cells shift from the GO/G1
phases to the S and G2/M phases (Fig. 3). Additional
experiments suggest that Hyalgan@”seffects are likely
due to the interaction of HA with the cell surface via a
CD44 receptor (Fig. 6), in agreement with previous results [5,14,37].
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Fig. 5. Microscopic appearance of U937 macrophages exposed to a high concentration of Hyalgan” for 72-168 h. Cells were cultured with 1 mg/mL
Hyalgan- (experimental) or PBS (control). Beginning at 72 h, increasing numbers of experimental cells exhibited reduced size, increased granularity,
budding, and fragmentation, morphological features consistent with apoptosis. Cells were imaged using Hoffman phase contrast optics and a Sony
390 digital camera.

Hyalgan@,as shown in this study, has regulatory influences on the growth dynamics of U937 macrophages
by differentially affecting both cellular proliferation and
cell death. However, the time course of Hyalgan@”sinhibitory effect on proliferation differs from the time of its
effect on apoptosis. The Hyalgan@-induced slowing of
proliferation was immediate and progressive. HyalganO
most likely slowed early cell cycle progression by preventing G1 to S cell cycle transition. It also increased S
to G 2 phase transition and reduced mitotic activity.
Notably, only proliferation was affected during the first
72 h of Hyalgan@exposure whereas both proliferation
and cell death were influenced thereafter. After 72 h,
marked decreases in the number of GOG1 cells ac-

companied substantial increases in the numbers of S and
G2/M cells. This temporal delay suggests that apoptosis
and cell death, but not slowing of proliferation, result from mechanisms which require at least 72 h to
complete. These mechanisms probably involve geneexpression and protein synthesis, events consistent with
ligand-induced apoptosis [26,34].
The results of this study suggest that differences in
HA-receptor binding and cross-linking may underlie
Hyalganm”sdifferential effects on cell growth. In this
study a high dose of high molecular weight HA inhibited proliferation, in agreement with previous studies [ 12,15,19], and induced apoptosis whereas lower
doses induced proliferation without apoptosis. These
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Fig. 6. Macrophage binding of HA via surface CD44 receptors. U937
cells were incubated with a FITC-conjugated anti-CD44 antibody or
with a FITC-conjugated mouse IgGl antibody as an isotype-negative
control. Additional cells were incubated with a FITC-conjugated HA
or with an antLCD44 antibody followed by washing and incubation
with the FITC-conjtigited H A . Relative fluorescent intensity was measured by flow cytomztry.

differential effects suggest that HA binding to CD44
without receptor cross-linking, as might occur with a
high dose of HA, are required for inhibition of proliferation and apoptosis induction. Support for this
mechanism is derived from previous reports showing
that treatment with anti-CD44 antibody alone induced
cellular apoptosis [ 14,17,39] or inhibited proliferation
[ 1 I]. Conversely, extensive receptor cross-linking, as
would occur with low HA concentrations or with small
HA molecules, would be expected to induce proliferation, as has been shown previously [33,40].

By contrast, the effects of Hyalgan@ on apoptosis
required at least 72 h to be detected. Following an intraarticular Hyalgan@ injection, at least two mechanisms
might contribute to increased apoptosis, in view of HA's
relatively short half-life. First, the detection of apoptotic
cells lags behind apoptosis induction by 72 h [8,16].
Thus, in a clinical setting apoptosis might be induced
soon after HA exposure, but apoptotic cells might not
be detectable for an additional 72 h. Apoptosis induction could continue as the intra-synovial HA concentration declines due to its relatively short half-life.
Second, the concentrations of commercial HA preparations are considerably higher than 1 mg/mL. Even
allowing for dilution with synovial fluid and disappearance due to its half-life, the HA concentration after
72 h could be 1 mg/mL or higher. This sustained high
concentration of HyaIgan@ could inhibit macrophage
proliferation and induce apoptosis for several days.
Other studies have shown that high molecular weight
HA at a high concentration also inhibits macrophage
phagocytic activity [I31 as well as the secretion of the
prostaglandins [2], reactive oxygen species [36],and nitric oxide [38]. Consequently, another mechanism for
Hyalgan@'s anti-inflammatory effect is reduced inflammatory activity. Together these two mechanisms support the efficacy of intra-articular injections of high
molecular weight HA as a long-term treatment for the
pain of OA.
The present study was performed using a single
preparation of HA with a defined size range. While the
use of a single preparation was advantageous for the
present study, the results cannot be extended to other
HA formulations of different size and/or composition.
Future studies will need to examine the effects of these
multiple parameters.
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The efficacy of intra-articular Hyalgan@injections as
a treatment for the pain of OA is likely due, in part, to
the dramatic reduction of inflammatory macrophages via reduced proliferation and induced apoptosis,
as presented in this study. Chronic inflammatory reactions, as in OA, are characterized by the accumulation and proliferation of inflammatory cells, including
macrophages, in connective tissue where their chronic
activation is perpetuated and leads to severe tissue
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